fbpx
  • Filter By Topic

January 21, 2020

Prevalence of Active Epilepsy, Lifetime Epilepsy Prevalence, and Burden of Epilepsy in Sub-Saharan Africa from Meta-Analysis of Door-to-Door Population-Based Surveys

This study estimates the active (9/1000) and lifetime (16/1000) epilepsy with a remarkable burden of the disease in Sub-Saharan Africa.

January 16, 2020

Latin American Summer School on Epilepsy Allows Scientists and Clinicians to Empathize With Their Patients Through Art

Participants of LASSE XIII demonstrated an ability to empathize with their patients in retrospect by portraying the inner feelings of division and imprisonment of those having seizures.

January 16, 2020

Systematic Review Highlights That Clinicians Should Be Aware of Possible Skin-related Drug Reactions to Levetiracetam

This study states that clinicians should be aware of the possible cutaneous adverse drug reactions induced by levetiracetam to avoid the development of a potentially fatal condition.

January 16, 2020

Epilepsy Research Findings: January 2020

Recent epilepsy research news includes findings about "silencing" neurons to gain seizures control, enhanced understanding of how epilepsy affects memory, and more.

related news
January 15, 2020

New Small Molecule to Treat Alzheimer’s Disease and Dravet Syndrome

Researchers have shown therapeutic efficacy of a new experimental drug in mouse models of Alzheimer's disease and a rare genetic form of epilepsy known as Dravet syndrome.

January 15, 2020

FANS Trial Testing Ketone Supplementation to Help Control Seizures in Children With Angelman Syndrome

A clinical trial is evaluating the safety and tolerability of a nutritional formulation containing the ketone beta-hydroxybutyrate (BHB) as a treatment to help control seizures in children with Angelman syndrome.

related news
January 14, 2020

Peptide Reduced Epileptic Seizures in Human Brain Tissue

Researchers at Lund University in Sweden have used a neuropeptide to successfully reduce seizure-like activity in tissue from patients with drug-resistant epilepsy.

January 13, 2020

Study Finds Cannabidiol (Epidiolex®) Effective in Subjects with Refractory Epilepsy with or without Simultaneous Use of Clobazam

Changes in norclobazam and clobazam levels do not have a clinically significant correlation with changes in weekly seizure frequency for those taking cannabidiol with clobazam.

January 13, 2020

Assessing Various Sensorimotor and Cognitive Functions in People with Epilepsy is Feasible with Robotics

Researchers state that their robotic paradigm can detect impairments in various sensorimotor and cognitive functions across the population with epilepsy.

related news
January 13, 2020

Taro Pharmaceuticals Press Release: Voluntary Nationwide Recall of Lamotrigine Tablets USP, 100 mg, 100 Count Bottles

Taro Pharmaceuticals U.S.A., Inc. (“Taro” or the “Company”) is voluntarily recalling one (1) lot of Lamotrigine 100 mg Tablets, Lot # 331771 (expiration date June 2021) in 100 count bottles, NDC 51672-4131-1 to the consumer level. This single lot of Lamotrigine 100 mg Tablets Lot #331771 (expiration date June 2021) was found to have been cross-contaminated with a small amount of another drug substance (Enalapril Maleate) used to manufacture another product at the same facility.This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200110005522/en/Risk Statement: Use of Lamotrigine 100 mg Tablets could potentially result in exposure to a small amount of Enalapril Maleate, if present in the product in question. Enalapril Maleate is a drug substance indicated for hypertension and congestive heart failure. There is potential with chronic exposure to Enalapril Maleate to impact users particularly if they are small children or pregnant women. Enalapril Maleate is also associated with risk of birth defects in a developing fetus. Therefore, there is risk associated with the continued, long-term use of Lamotrigine 100 mg Tablets, Lot # 331771 (expiration date June 2021).Taro has not received any product complaints or adverse events related to contamination of this product with Enalapril, or any complaints or adverse events that are associated specifically with this recall. Taro will continue to actively monitor for any and all adverse event reports that may be received, in compliance with FDA regulatory requirements.Lamotrigine 100 mg Tablets are indicated for Epilepsy and Bipolar disorder. This product is packaged in white plastic bottles with screw cap closure, and each bottle contains 100 tablets. Each bottle is labeled to indicate the name of the product, Lamotrigine Tablets USP, 100 mg, the NDC #51672-4131-1 (see image of container label below), the lot number 331771 and expiration date of June 2021.Lamotrigine 100 mg Tablets, Lot # 331771 were distributed to wholesale distributors in the US market between August 23 and August 30, 2019. These wholesale customers may have further distributed Lot # 331771 to retail pharmacies for prescription dispensing to patients who were prescribed 100 mg Lamotrigine Tablets.Taro is notifying its distributors and customers by Phone, E-mail, and Letters via US Mail and is arranging for return of any containers or quantities of Lamotrigine 100 mg Tablets, Lot # 331771 (exp. June 2021). Consumers that have any quantities of Lamotrigine 100 mg Tablets, Lot # 331771 being recalled should stop using this product and return it to the pharmacy that dispensed it. Retailers, pharmacies and distributors should stop distributing or dispensing this product and return it to Taro.Consumers with questions regarding this recall can contact Taro by calling 1-866-923-4914 or by e-mail at TaroPVUS@taro.com, Monday through Friday between 7:00 AM and 7:00 PM US Central Time. Consumers should contact their physician or healthcare provider if they have experienced any problems that may be related to taking or using this drug product.Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA's MedWatch Adverse Event Reporting program either online, by regular mail or by fax.Complete and submit the report Online Regular Mail or Fax: Download form or call 1- 800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA-0178This recall is being conducted with the knowledge of the U.S. Food and Drug Administration.

related news
January 13, 2020

Neurelis Press Release: FDA Approval for Seizure Rescue Medication VALTOCO

VALTOCO is the first nasal spray approved by the FDA as a rescue treatment for people with epilepsy aged 6 and older

January 9, 2020

Behind the Seizure® Program Further Expands Access to Genetic Testing for Children to Speed the Diagnosis of Genetic Epilepsy

The program will be expanded to make no-charge testing available for healthcare providers to order for any child under the age of eight who has an unprovoked seizure.

1 2 92

Stay up-to-date with CURE news & epilepsy research discoveries.

Required field missing
Email address invalid